Highlight Articles in Int J Ophthalmol Vol.14 No.8 2021

 

CLINICAL RESEARCH

Progression rate to primary angle closure following laser peripheral iridotomy in primary angle closure suspects: a randomized study

Da-Peng Mou, Yuan-Bo Liang, Su-Jie Fan, Yi Peng, Ning-Li Wang, Ravi Thomas

 

This study aims to report the progression rate (PR) to primary angle closure (PAC) following laser peripheral iridotomy (LPI) in PAC suspects (PACS). Totally 134 bilateral PACS, defined as non-visibility of the posterior trabecular meshwork for 180 degrees on gonioscopy were randomly assigned to undergo LPI in one eye. Gonioscopy and Goldmann applanation tonometry were performed prior to, on day 7 and 12mo’ post LPI. The results show that LPI can open some of the occludable angle in the majority of eyes with PACS, but 67% continue to have non-visibility of the trabecular meshwork for over 180 degrees.

 

对照译文

激光虹膜周边切除术后可疑原发性房角关闭患者进展为原发性房角关闭的比率:一项随机研究

 

该研究旨在报告可疑原发性房角关闭(PACS)患者在激光虹膜周边切除术(LPI)后向原发性房角关闭(PAC)的进展比率(PR)。双侧PACS患者共134人随机接受单眼LPIPACS定义为前房角镜检查≥180°的后部小梁网不可见。术前、术后第7天和术后12个月分别进行前房角镜检查和Goldmann眼压测量。结果显示,LPI能使大多数PACS患者部分关闭房角打开,但仍有67%的患者小梁网不可见范围超过180°。

PDF Fulltext

 

CLINICAL RESEARCH

Macular density alterations in myopic choroidal neovascularization and the effect of anti-VEGF on it

Jian-Bo Mao, Yi-Run Shao, Jia-Feng Yu, Xin-Yi Deng, Chen-Yi Liu, Yi-Qi Chen, Yun Zhang, Zhao-Kai Xu, Su-Lan Wu, Li-Jun Shen

 

This study analysed macular microvascular alterations in myopic choroidal neovascularization (mCNV) and the efficiency of anti-vascular endothelial growth factor (anti-VEGF) therapy for mCNV by optical coherence tomography angiography (OCTA). The results showed macular vessel density decreased, foveal avascular zone (FAZ) turned smaller and more irregular in mCNV eyes. Anti-VEGF therapy is efficient for mCNV but unable to changing vessel density and FAZ and eliminates CNV lesions completely in most cases, the mean reduction ratio is 50.32%, the bigger mCNV lesions have lower reduction ratio.

 

对照译文

近视性脉络膜新生血管中黄斑密度的改变及抗血管内皮生长因子的作用

 

该研究应用光学相干断层扫描血管造影(OCTA)分析了近视性脉络膜新生血管(mCNV)黄斑微血管的改变以及抗血管内皮生长因子治疗的有效性。结果表明,mCNV黄斑血管密度降低,中央凹无血管区变小且不规则。抗血管内皮生长因子治疗mCNV有效,但在大多数病例中并不能改变血管密度和中央凹无血管区以及完全消除脉络膜新生血管病变。mCNV病变范围越大减少率越低,平均减少率为50.32%

PDF Fulltext

 

REVIEW ARTICLE

Therapeutic effect of Keap1-Nrf2-ARE pathway-related drugs on age-related eye diseases through anti-oxidative stress

Zi-Yan Cai, Meng-Die Fu, Ke Liu, Xuan-Chu Duan

 

Age-related eye diseases, including cataract, glaucoma, diabetic retinopathy (DR), and age-related macular degeneration (AMD), are the leading causes of vision loss in the world. Several studies have shown that the occurrence and development of these diseases have an important relationship with oxidative stress in the eye. The Keap1-Nrf2-ARE (Kelch-like ECH-associating protein 1-nuclear factor erythroid 2 related factor 2-antioxidant response element) pathway is a classical pathway that resists oxidative stress and inflammation in the body. This pathway is also active in the development of age-related eye diseases. A variety of drugs have been shown to treat age-related eye diseases through the Keap1-Nrf2-ARE pathway. This review describes the role of oxidative stress in the development of age-related eye diseases, the function and regulation of the Keap1-Nrf2-ARE pathway, and the therapeutic effects of drugs associated with this pathway on age-related eye diseases.

 

对照译文

Keap1-Nrf2-ARE通路相关药物通过抗氧化应激对年龄相关性眼病的治疗作用

 

年龄相关性眼部疾病,包括白内障、青光眼、糖尿病视网膜病变(DR)和老年性黄斑变性(AMD),是全世界患者视力丧失的主要原因。一些研究表明,这些疾病的发生和发展与眼部的氧化应激相关。Keap1-Nrf2-ARE通路是抵抗体内氧化应激和炎症的经典途径,并且参与年龄相关性眼部疾病的进展。已有多种药物通过作用于Keap1-Nrf2-ARE通路治疗年龄相关性眼病。该综述介绍了氧化应激在年龄相关性眼病发展中的作用,Keap1-Nrf2-ARE通路的功能和调节,以及与该通路相关的药物对年龄相关性眼病的疗效。

PDF Fulltext

 

REVIEW ARTICLE

Newly-found functions of metformin for the prevention and treatment of age-related macular degeneration

Kuan-Rong Dang, Tong Wu, Yan-Nian Hui, Hong-Jun Du

 

Recent clinical studies revealed that metformin (MET) can reduce the occurrence or delay the progression of age-related macular degeneration (AMD) but the effector mechanisms of MET in this process remain unclear. In this paper, the authors review recent progress in the prevention and treatment of AMD by using MET and the possible mechanisms of these effects. The authors believe that understanding the mechanism by which MET affects AMD and the implementation of multicenter clinical studies to validate the efficacy and administration route of MET will provide theoretical data and dosing guidance for MET to enable AMD prevention and treatment.

 

对照译文

二甲双胍预防和治疗年龄相关性黄斑病变的新功能

 

近年来临床研究表明,二甲双胍(MET)可以减少或延缓年龄相关性黄斑病变(AMD)的发生或进展,但MET在这一过程中的作用机制尚不清楚。作者就MET预防和治疗年龄相关性黄斑病变的研究进展及可能的作用机制进行了综述。作者认为,了解MET影响AMD的机制,并开展多中心临床研究验证MET的疗效和用药途径,将为MET预防和治疗AMD提供理论依据和用药指导。

PDF Fulltext

 

To view more excellent articles for free please visit Here.